INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Our pipeline consists of first in class therapies designed to …

INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer.

A leading biotechnology company focused on modulating components of the innate immune system to activate a response against cancer and Alzheimers.

INmune Bio is targeting two key components of the innate immune system to treat Neurologic Disease and Cancer:

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dem... INmune Bio Announces Successful Completion of First Commercial Pilot-Scale …

Jul 23, 2024 · INmune Bio is currently conducting a trial of INKmune TM in the treatment of metastatic castration-resistant prostate cancer. Preliminary results from that trial are expected later this year.

The Board of Directors of INmune Bio, Inc. has adopted a Code of Ethics applicable to employees, directors, consultants and vendors, a link to which can be found below on this page.

INmune Bio confirmed that additional MRI analyses from the MINDFuL trial are ongoing and will be presented when available. These forthcoming data are expected to provide a broader picture of …

4 days ago · Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations …

We aim to collect the most relevant data only, to ensure a minimal burden to participants and a speedy development of our therapeutics to patients in need. At INmune Bio, we are developing therapeutics …